Unmet treatment needs remain in multiple myeloma, particularly among patients with relapsed/refractory disease who have received multiple lines of therapy. This study evaluates a potential salvage approach of daratumumab-based retreatment in patients refractory to daratumumab and/or pomalidomide.
PREAMBLE (Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation) is an ongoing multinational observational study being conducted to evaluate real-world outcomes in patients with multiple myeloma. Here, researchers present preliminary efficacy analyses in patients with one line of prior therapy.
Ixazomib, Pomalidomide, and Dexamethasone Triplet Therapy in Patients with Double/Triple Refractory Myeloma
Novel triplet combinations are being evaluated in both the newly diagnosed and relapsed/refractory settings in multiple myeloma. This study evaluates the efficacy and safety of ixazomib, pomalidomide, and dexamethasone combination therapy in a heavily pretreated, high-risk patient population.
Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma
Payers seek to understand the value of myeloma treatment options by assessing outcomes relative to cost. This claims-based analysis assesses trends in novel therapy use, total healthcare costs, and survival outcomes among newly diagnosed multiple myeloma patients in the United States since 2000.
Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance: Data from the Connect MM Disease Registry
As more patients receive maintenance therapy for multiple myeloma, researchers seek to evaluate the impact of toxicities associated with long-term treatment on health-related quality of life in these patient populations.
The majority of patients with smoldering multiple myeloma do not receive active treatment. In this study, treatment of a high-risk population with lenalidomide and dexamethasone yielded favorable patient outcomes.
Treatment with a Novel HDAC6 Inhibitor plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Investigational agents with novel mechanisms of action continue to show promise in treating multiple myeloma. In this study, researchers report findings of a phase 1a/1b study evaluating an oral HDAC6 inhibitor.
Healthcare stakeholders have formulated a number of management approaches to ensure that patients receive appropriate therapies. Here, clinicians at Cleveland Clinic report on a response-adapted treatment protocol for newly diagnosed patients with multiple myeloma.
Page 13 of 19
Results 121 - 130 of 190
Results 121 - 130 of 190